DNAJB8 Rekombinanter Antikörper

DNAJB8 Rekombinant Antikörper für WB, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus, Ratte

Anwendung

WB, ELISA

Konjugation

Unkonjugiert

CloneNo.

251752B7

Kat-Nr. : 86763-3-RR

Synonyme

DJ6

---

• 

  WB analysis using 86763-3-RR

  Various lysates were subjected to SDS PAGE followed by western blot with 86763-3-RR (DNAJB8 antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: SW480-Zellen, fetales humanes Hirngewebe, HEK-293-Zellen, HeLa-Zellen, Maushirngewebe, Rattenhirngewebe

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:5000-1:50000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

86763-3-RR bindet in WB, ELISA DNAJB8 und zeigt Reaktivität mit human, Maus, Ratten

• Getestete Reaktivität: human, Maus, Ratte
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Rekombinant
• Typ: Antikörper
• Immunogen: DNAJB8 fusion protein Ag10899
• Vollständiger Name: DnaJ (Hsp40) homolog, subfamily B, member 8
• Berechnetes Molekulargewicht: 232 aa, 26 kDa
• Beobachtetes Molekulargewicht: 26 kDa
• GenBank-Zugangsnummer: BC029521
• Gene symbol: DNAJB8
• Gene ID (NCBI): 165721
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Protein-A-Reinigung
• Lagerungspuffer: PBS with 0.02% sodium azide and 50% glycerol
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

DNAJB8, a member of the DNAJ/HSP40 family of proteins, plays a crucial role in regulating chaperone HSP70 activity. It is known for its ability to suppress the aggregation of polyglutamine proteins through its C-terminal tail. Furthermore, DNAJB8 has been shown to inhibit TP53 through ubiquitin degradation in human colon cancer by directly interacting and upregulating MDR1, leading to increased oxaliplatin resistance. High levels of DNAJB8 in both colon tissues and serum are correlated with worse overall survival of colon cancer patients, suggesting that DNAJB8 level in serum sEV may serve as a potential biomarker for colon cancer and a promising therapeutic target for oxaliplatin-resistant cancer.